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To examine the relationship between growth hormone (GH) and insulin-like growth factor 1 (IGF1) in controlling postnatal
growth, we performed a comparative analysis of dwarfing phenotypes manifested in mouse mutants lacking GH receptor,
IGF1, or both. This genetic study has provided conclusive evidence demonstrating that GH and IGF1 promote postnatal
growth by both independent and common functions, as the growth retardation of double Ghr/Igf1 nullizygotes is more
severe than that observed with either class of single mutant. In fact, the body weight of these double-mutant mice is only
;17% of normal and, in absolute magnitude (;5 g), only twice that of the smallest known mammal. Thus, the growth
control pathway in which the components of the GH/IGF1 signaling systems participate constitutes the major determinant
of body size. To complement this conclusion mainly based on extensive growth curve analyses, we also present details
concerning the involvement of the GH/IGF1 axis in linear growth derived by a developmental study of long bone
ossification in the mutants. © 2001 Academic Press
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The growth (increase in size) of a mammalian organism is
effected predominantly by proliferative events outbalancing
apoptosis and increasing total cell number, with some
additional contributions by cell hypertrophy and deposition
of extracellular matrix. During mouse development, this
process begins in early embryogenesis (blastocyst stage) and
lasts until a steady state (balance between proliferation and
apoptosis) is reached postnatally, when a mouse attains a
determinate body size (;30 g) at about 4–5 months of age.
Growth is brought about by the operation of cellular
signaling pathways controlled by growth factors and hor-
mones. Growth factors are produced by many tissues and
exert mainly local (autocrine/paracrine) controls that pre-
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All rights of reproduction in any form reserved.ominate during embryogenesis, whereas hormones act
ystemically away from the sites of their production.
Among the classic growth factors, the IGFs (insulin-like
rowth factors; IGF1 and IGF2) were shown to be members
f a major growth-promoting signaling system (reviewed by
fstratiadis, 1998). IGF2 is essential for normal embryonic
rowth (DeChiara et al., 1990, 1991), whereas IGF1 is a
igand that has a continuous function throughout develop-
ent (Liu et al., 1993; Baker et al., 1993). Thus, the growth
ate of Igf1 nullizygotes, if they survive, continues to be
ower than normal postnatally, as it was during embryogen-
sis. As a consequence, these mutants, which have ;60%
f normal weight at birth (;60%N), become ;30%N at
steady state.
Postnatally, a major growth regulator is growth hormone
(GH), which has no apparent embryonic role, despite the
presence of its cognate receptor (GHR) in embryos (Garcı´a-
Arago´n et al., 1992; Pantaleon et al., 1997). Thus, absence of
GH action in mutant animals or experimental ablation of
the pituitary does not impair prenatal growth (reviewed by
Fowden, 1995). In most mouse strains, the growth of the
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142 Lupu et al.GH-deficient spontaneous mutants Snell (dwarf, dw), Ames
(df), and little (lit) is indistinguishable from that of wild-
type littermates for approximately the first 2 weeks after
birth, at which time growth retardation begins to be mani-
fested. Eventually, the Snell dwarfs (lacking both GH and
thyroid-stimulating hormone) reach a relative size of
;30%N, whereas the Ames and lit mice (possessing re-
sidual GH activity) become ;50%N in weight. These
dwarf mice (for reviews, see Watkins-Chow and Camper,
1998; Kioussi et al., 1999) carry, respectively, missense
mutations of the genes Pit1 (encoding a transactivator
essential for the expression of GH, prolactin, and thyroid-
stimulating hormone b subunit), Prop1 (encoding a trans-
activator essential for expression of Pit1 and expansion of
Pit1-controlled pituitary cell lineages), and Ghrhr (encoding
the receptor of the GH-releasing hormone). Although in-
valuable for a variety of studies, these spontaneous mouse
dwarfs are not ideal models to address questions about the
GH/IGF axis in postnatal growth, as they exhibit combined
pituitary hormone deficiencies and/or possess some re-
sidual GH activity. Similar drawbacks exist with studies
involving hypophysectomy, which removes not only GH
but also other hormones known to affect growth (especially
thyroid hormone regulators; see Williams et al., 1998).
Thus, to explore the relationship between GH and IGF1 in
growth control, we used an alternate genetic approach
based on the following considerations.
The original “somatomedin hypothesis” (Salmon and
Daughaday, 1957; for a review, see Daughaday, 1989;
Scanes and Daughaday, 1995) was proposed on the basis of
results demonstrating that GH (somatotropin) stimulated
sulfate incorporation into cartilage indirectly through a
serum factor (somatomedin; mediator of the effects of
somatotropin). In its more general form, the hypothesis
posited that GH stimulates the hepatic production of cir-
culating somatomedin (i.e., IGF1), which then mediates the
hormonal effects on target tissues. However, despite evi-
dence for an apparent endocrine role of the plasma IGF1
(reviewed by Zapf, 1998), its involvement in growth control
was recently disputed on the basis of results with a condi-
tional Igf1 gene knockout in mice (Sjo¨gren et al., 1999;
akar et al., 1999; see Results and Discussion). Moreover,
direct effects of GH on cartilage, apparently mediated by
locally produced and not by circulating IGF1 (Isaksson et
al., 1982; Nilsson et al., 1986; Schlechter et al., 1986;
eviewed by Isaksson et al., 1987; Ohlsson et al., 1998),
emained undetectable in the pioneering experiments
Salmon and Daughaday, 1957) for technical reasons
Salmon and Burkhalter, 1997). Finally, in regard to IGF1-
ndependent action of GH, a “dual effector theory” was
roposed (Green et al., 1985), according to which GH
stimulates the differentiation of progenitor cells, making
them responsive to IGF1.
Although the original version of the somatomedin hy-
pothesis is not tenable, the important issues pertaining to
the exact relationship between GH and IGF1 and the
relative magnitudes of their contributions to growth have
Copyright © 2001 by Academic Press. All rightnot been resolved yet. In fact, in regard to bone develop-
ment, the picture is still quite unclear, while similar
confusion exists when other IGF1 or GH target tissues are
considered.
To investigate genetically the relationship between GH
and IGF1 in postnatal growth, we sought to generate
double-mutant mice lacking the actions of both GH and
IGF1 and compare their phenotype with the phenotypes of
the respective single mutants. For this purpose, we used
available Igf1 mutant mice (Liu et al., 1993) and generated
mutants lacking GH action by knocking out the gene
encoding GHR. While this work was in progress, a report
appeared also describing targeted inactivation of the Ghr
gene by a different strategy (deletion of the 39 portion of
exon 4 and part of the downstream intron; Zhou et al.,
1997). Mice lacking GHR function are potential models of
Laron-type dwarfism, a growth-retardation disorder result-
ing from mutations in the human Ghr gene (see Rosenfeld
et al., 1994; Laron, 1999; Kopchick and Laron, 1999).
MATERIALS AND METHODS
Ghr Gene Targeting and Breeding of Mutants
To isolate mouse clones carrying portions of the Ghr gene, we
creened a genomic l phage library from strain 129/Sv with a
partial cDNA probe synthesized by RT-PCR using mouse liver
RNA and the primers 59-TCCACCCATTGGCCTCAACTGGA-
CTT-39 (forward; in exon 6) and 59-TGGCGGATCCTCTGAA-
GCTGGTGAT-39 (reverse; in exon 8a; Edens et al., 1994). A
targeting vector was then constructed from subcloned genomic
fragments in several steps. For selection of targeted clones, neomy-
cin (neo) and thymidine kinase (tk) gene cassettes placed in
transcriptional orientation opposite to that of the endogenous locus
were included in the construct (Fig. 1a). The final product (cloned
into pBluescript SK(1); Stratagene) consisted of a 59 genomic
fragment containing exon 6 (9.6 kb), from a NotI site (initially in
the phage polylinker) to an XbaI site, the neo cassette (1.7 kb; XbaI
to XbaI), a downstream Ghr genomic fragment (2.4 kb; from an
XbaI site to a SalI site initially present in the phage polylinker), and
the tk cassette (1.85 kb; SalI to XhoI). Thus, a 4-kb XbaI–XbaI Ghr
genomic fragment containing exons 7, 8a, and 8 was replaced with
the neo cassette.
Linearized targeting vector DNA was introduced by electropora-
tion into 129/Sv ES cells (CCE-33) and, after drug selection, DNA
of resistant clones was analyzed by Southern blotting (Figs. 1a and
1b). In addition, a neo probe was used to demonstrate that single-
copy integration had occurred in the targeted ES cells. To generate
chimeras, cells of a targeted clone were injected into host blasto-
cysts of C57BL/6J like mice that were transferred into uteri of
pseudopregnant females.
Male chimeras were mated with C57BL/6J females and F1
heterozygous progeny were intercrossed. To generate Ghr(1/2)/
Igf1(1/2) double heterozygotes, we crossed Ghr(1/2) mutants (129
Sv/C57BL/6J) with heterozygous mice (MF1/DBA) carrying a tar-
geted mutation of the Igf1 gene (Liu et al., 1993; Baker et al., 1993,
1996). The particular genetic background of Igf1 mutants was
chosen on the basis of empirical observations, to increase the
frequency of surviving nullizygotes obtained in subsequent crosses
(there is a strain-dependent, high incidence of neonatal lethality
s of reproduction in any form reserved.
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143Growth Control by IGF1 and Growth Hormoneamong Igf1 nullizygotes; Liu et al., 1993). The Ghr/Igf1 double
heterozygotes and the progeny derived from their intercrosses,
including double nullizygotes, carried components of four strain
backgrounds in variable mixtures. Double null mutants were also
obtained by intercrossing Ghr(2/2)/Igf1(1/2) parents generated
from double heterozygote intercrosses (double nullizygotes cannot
be intercrossed because both sexes of Igf1 null survivors are
infertile; Baker et al., 1996). Mice were genotyped for the Ghr
mutation as described above for targeted ES cells and for the Igf1
mutation as described previously (Liu et al., 1993).
RNA Analysis
Northern blots of total liver RNA (20 mg) from wild-type,
Ghr(1/2) and Ghr(2/2) mice were hybridized with a 586-bp probe
representing a mouse Ghr cDNA fragment (exons 1 through 6)
btained by RT-PCR using the primers 59-CAGGTCTTCTTAAC-
TTGGCACTGGC-39 (forward) and 59-AAGTCCAGTTGAGG-
CAATGGGTGGA-39 (reverse).
Semiquantitative RT-PCR assays of steady-state Igf1 mRNA
sing b-actin mRNA as a standard were performed in duplicate
using the following primer pairs (the members of each pair repre-
sent sequences in different exons of the respective genes, to avoid
amplification of genomic DNA potentially contaminating the
samples): 59-ACCAAAATGACCGCACCTGC-39 (Igf1 forward),
59-AACACTCATCCACAATGCCTGTC-39 (Igf1 reverse), 59-GAC-
AACGGCTCCGGCATGTGCAAAG-39 (actin forward), and 59-
TTCACGGTTGGCCTTAGGGTTCAGGG-39 (actin reverse). The
conditions for linear Igf1 amplification (midlog phase of PCR) were
denaturation at 94°C (15 s), annealing at 57°C (15 s), and extension
at 60°C (30 s). The number of cycles varied between samples (liver
11; kidney, ovary, and testis 15; and brain, heart, and lung 18).
Except for the annealing temperature (70°C), the conditions for
actin amplification (11 cycles) were the same. For each organ, the
Igf1 and b-actin reaction products were mixed, fractionated on a
% NuSieve agarose gel, and transferred onto nylon membranes. In
his Southern analysis, the respective PCR products were used as
ybridization probes and the signals were quantitated using a
hosphorImager (Molecular Dynamics). From these readings, ratios
f Igf1 and b-actin signal intensities were calculated (normaliza-
tion) and then compared between mutant and wild-type specimens.
Statistically significant differences in pairwise comparisons of
these and other data were evaluated using Student’s t test at a
rejection level of 5%.
Protein Analysis
Protein amounts were determined by BCA assays (Pierce). West-
ern analyses were performed as described (Eggenschwiler et al.,
1997). For analysis of GHR by Western blotting, we used hepatic
microsomal protein extracts (Smith and Talamantes, 1987) from
17-day-pregnant Ghr(2/2) and control females. The primary anti-
body (As 2941) against the intracellular domain of the mouse GHR
was a gift from Dr. G. P. Frick (Frick et al., 1994). Attempts to
visualize a truncated protein in the mutants by Western analysis
using a commercially available antibody against the N-terminal
domain of GHR/GHBP (Anawa, Switzerland) were unsuccessful.
For Western blotting or RIA, serum IGF1 was partially purified by
acid–ethanol cryoprecipitation (Breier et al., 1991) and detected
with an anti-human IGF1 monoclonal antibody (R&D Systems).
Radioimmunoassays were performed using a kit (Nichols Insti-
tute). The lowest of three serum dilutions used in these RIA
Copyright © 2001 by Academic Press. All rightmeasurements was 1:50 (higher serum concentrations generated
nonparallel competition curves and high background even with
negative control sera from Igf1 null mice). The primary antibody
used for GH detection was provided by Dr. A. F. Parlow and the
National Hormone and Pituitary Program (Baltimore, MD).
Bone Histology and Morphometry
Tibiae and femora from animals perfused with buffered formalin
were decalcified for 3–4 days in Cal-EX II solution (Sigma); washed
for 24 h at 4°C in a solution containing 0.25 M sucrose, 0.2 M
glycine, and 0.1 M sodium phosphate buffer (pH 7.3); dehydrated;
cleared with toluene; and embedded in paraffin. Paraffin blocks
were sectioned at 6–8 mm and stained with hematoxylin and eosin.
Measurements were taken on cleaned bones from perfused
nimals with a dial caliper (Scienceware). The measurement of
piphyseal width corresponds to the widest dimension, while that
f diaphyseal width is the average of two determinations per tibia,
bove and below the point where the fibula joins the diaphysis
istally.
Morphometry was performed on photographs of longitudinal
ections (close to the midline of the bone) taken with a Nikon
igital camera. The total height of the growth plate (GP) was
onsidered the distance between the two chondrosseous junctions:
roximal (border between the secondary ossification center and the
hondrocytes of the resting zone; see Results and Discussion) and
istal (border between the hypertrophic zone and the beginning of
picules of trabecular bone). To measure the heights of the prolif-
rative and hypertrophic zones (PZ and HZ), their borders were
elineated on the basis of morphological criteria. Thus, the prolif-
rative zone was measured from the top of the columns of chon-
rocytes to the border of the hypertrophic zone that corresponds
pproximately to the point where the ratio of cell width to cell
eight reaches ;2 (see Vanky et al., 1998). The distance between
his point and the distal chondrosseous junction was considered
he height of the hypertrophic zone. We defined the height of each
esting zone (RZ; see Results and Discussion) by subtraction: RZ 5
P 2 (PZ 1 HZ).
BrdU Labeling
Labeling of chondrocytes with bromodeoxyuridine (BrdU) was
performed as described (Eggenschwiler et al., 1997). The animals
were sacrificed 1 h after injection of BrdU at postnatal day 22 (p22).
Stained and unstained cells were counted in one rectangle per
section, using four sections close to the midline per animal, and
four animals per phenotype (16 determinations per growth plate of
each phenotype). The same size of rectangle, always positioned
within the zone of proliferating chondrocytes, was used for all
sections regardless of phenotype. Values were expressed as percent-
ages of the total number of cells that were BrdU positive. The
average and the standard error were calculated from the means of
the four animals for each genotype.
In Situ Hybridization
Nonisotopic in situ hybridization with digoxigenin-labeled
probes was performed on dewaxed paraffin sections. After rehydra-
tion, we followed a procedure described previously for fixed frozen
sections (Schaeren-Wiemer and Gerfin-Moser, 1993). For detection
of Igf1 transcripts we used a full-length Igf1 cDNA (GenBank
Accession No. AI314558). The probe to examine Ghr expression
s of reproduction in any form reserved.
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144 Lupu et al.was the same as that described above for Northern analysis. The
hybridization signal was amplified with the TSA Biotin System
(NEN). The probes used for detection of collagen mRNAs were
described previously (Lee et al., 1994).
Growth Analysis
Despite frequent weight measurements, in the dataset of derived
values, not all mice were measured on each and every day, while
the times of determinations often differed between litters. For
these reasons, postnatal growth curves of wild-type and mutant
mice were constructed and fitted as follows: First, to determine
average absolute growth rates (weight changes per day), we sub-
jected the entire set of data for each phenotype to statistical
analysis using maximum-likelihood methods (described in detail at
http://www.columbia.edu/;ae4/GHR_IGF1_AP.html). The plots
of these initial growth rates have rather jagged forms, but when
they are transformed to conventional growth curves (plots of
cumulative weight versus age), the estimates follow paths that are
quite smooth (i.e., fluctuations of values are only a minor, not a
prominent, feature). To rederive rate curves that would also be
smooth, we used a two-step procedure based on the consideration
that cumulative postnatal growth curves are best fitted with a
logistic equation W 5 A/1 1 exp[2b(t 2 c)], where W and A are
the weight at time t and the asymptotic weight, respectively, while
b and c are constants. A second consideration was that, for the
period of displayed observations (100 postnatal days), growth is
clearly triphasic. Thus, between an early neonatal growth period
(;2 weeks) and a growth spurt after weaning, there is a period of
considerable decline in growth rate. However, the growth of
wild-type mice during this intermediate period simply slows down,
whereas in the mutants described here growth becomes negative.
On the basis of these features, the weight data were fitted simul-
taneously using a computer program (SigmaPlot) by summation of
three logistic functions with different sets of A, b, and c values
(Koops, 1986; Koops et al., 1987). Moreover, we found empirically
hat a faster and better fit accommodating the data of negative
rowth is achieved if a negative sign is assigned to the second of the
hree equations, giving positive values to the other two. (In contrast
o the mutants, the final fit of wild-type data was insensitive to the
ign of the second equation.) From each fit, curves of predicted
bsolute growth rates (dW/dt) were derived (same as the initial rate
urves, but smooth) by subtracting the value of cumulative weight
t each day (W i) from that estimated for the previous day (W i21).
urthermore, for even more sensitive comparisons, each absolute
rowth rate was transformed to a specific growth rate [i.e., growth
ate per unit size; (dW/dt) 3 (1/W)] using weight values for
ormalization: (W i 2 W i 2 1)/[1⁄2 3 (W i 1 W i 2 1)].
Organ weights were determined as described (Eggenschwiler et
l., 1997). Body lengths (from the tip of the nose to the base of the
ail) were measured on anesthetized animals stretched on top of a
uler.
RESULTS AND DISCUSSION
Analysis of Ghr(2/2) Mutants
Targeted disruption of the mouse Ghr gene. To gener-
ate mutants lacking GH functions, as required by our
experimental design (see Introduction), we chose to target
Ghr rather than the Gh gene itself, so that we could
Copyright © 2001 by Academic Press. All rightscertain at the same time whether the embryonic expres-
ion of GHR plays some indispensable physiological role (it
urned out that it does not).
The mouse gene encoding GHR is large (.90 kb) and
ontains more than 2 alternate 59 noncoding exons and 11
oding exons, the last 2 of which (9 and 10) encode the
ntracellular domain of the receptor (Moffat et al., 1999).
he same gene also encodes GH-binding protein (GHBP),
hich corresponds to the extracellular domain of GHR and
s found in the circulation associated with GH. In rodents,
ut not in all examined species, the Ghbp (;1.2 kb) and Ghr
;4.2 kb) mRNAs are generated, respectively, by alternate
plicing of exon 7 either to exon 8a (encoding the
-terminal domain of GHBP and the 39 noncoding region of
he corresponding mRNA) or to exon 8 (encoding the
ransmembrane domain of GHR).
To generate a null mutation of the Ghr gene, we used a
argeting vector that would replace exons 7, 8a, and 8 with
neo cassette (Fig. 1a). The targeted allele (Figs. 1a and 1b)
as designated Ghrex7-8. Ghr(2/2) mice were obtained at
the expected Mendelian ratios. They exhibited postnatal
growth retardation (see below), but they were viable and
fertile, although, as previously described for a similar mu-
tation (Zhou et al., 1997), the sexual maturation of females
was delayed and the litter sizes were small.
To demonstrate that Ghrex7-8 was a null allele, we first
performed Northern analysis of total liver RNA using a
cDNA probe (exons 1–6) able to recognize both the Ghr and
the Ghbp mRNA species (Fig. 1c). The results showed that
the 1.2-kb mRNA species encoding GHBP was not present
in Ghr(2/2) mutants, as expected from the deletion of exon
8a containing the Ghbp mRNA polyadenylation signal. On
the other hand, a transcript with a size similar to that of
wild-type Ghr mRNA (4.2 kb) was still present in the
mutants, but at a significantly reduced level (Fig. 1c). This
mutant transcript was predicted to lack the short exons 7
and 8 (0.26 kb), but the small size difference from wild-type
could not be monitored convincingly by a shift in electro-
phoretic mobility. Thus, after RT-PCR using primers in
exons 6 and 10, we sequenced a region of the mutant
mRNA and demonstrated directly that splicing had oc-
curred between exons 6 and 9, resulting in a predicted frame
shift and the appearance of a stop codon at the beginning of
exon 9 (Fig. 1d). Not unexpectedly, therefore, the amount of
the mutant Ghr mRNA was significantly reduced in com-
parison with the controls, considering that a surveillance
mechanism is in operation, which detects and degrades
abnormal mRNAs carrying nonsense codons that can lead
to premature translational termination (Frischmeyer and
Dietz, 1999).
On the basis of the mutant mRNA analysis, we inferred
that any truncated GHR synthesized in Ghr(2/2) embryos
would lack an intracellular domain. Consistent with this
expectation, Western analysis demonstrated that an anti-
body against the intracellular GHR domain failed to recog-
nize GHR in preparations of hepatic microsomes from
Ghr(2/2) mutants, in contrast to wild-type controls (Fig.
s of reproduction in any form reserved.
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SFIG. 1. Targeting of the mouse Ghr locus and molecular analyses of mutants. (a) The restriction map in the region of exons 6–10 (black
rectangles) of the Ghr/Ghbp gene (top), the targeting construct (middle) used for gene disruption by homologous recombination (denoted by large
X symbols), and the structure of the derived (arrow) targeted allele (bottom) are shown. The transcriptional orientations of the neo cassette
(replacing the deleted exons 7, 8a, and 8) and of the tk cassette are indicated with arrows. The wavy line represents plasmid vector sequence. N
indicates a NotI site used to linearize the replacement vector. Other restriction sites are EcoRI (E), HindIII (H), XbaI (X), and EcoRV (RV). The
position of the probe (a 1.0-kb Sau3A fragment located in the Ghr locus downstream of the 39 region of homology present in the vector) that was
used for Southern analyses of ES cell clones and mice is indicated, and the sizes (in kb) of the endogenous and targeted HindIII and EcoRV genomic
DNA fragments recognized by this probe are shown. (b) Examples of Southern blots of HindIII- and EcoRV-digested genomic DNA from targeted
(T) and nontargeted (NT) ES cell clones hybridized with the probe shown in (a). (c) Northern analysis of liver RNA isolated at p60 from wild-type
(1/1), heterozygous (1/2), and nullizygous (2/2) Ghr mice. The membrane was hybridized with a Ghr/Ghbp cDNA probe (exons 1–6) and then
tripped and rehybridized with a mouse glyceraldehyde-3-phosphate dehydrogenase (Gapd) cDNA probe (detecting a 1.2-kb transcript), to provide
loading control. (d) Results of DNA sequencing of cloned RT-PCR products using liver Ghr(2/2) mutant mRNA template and the indicated
rimers (arrows). The sequence demonstrates that, in the mRNA from the mutated locus, splicing has occurred between exon 6 and exon 9,
esulting in the generation of a stop codon (TAA; bold letters) at the beginning of exon 9. (e) Western analysis of protein extracts from hepatic
icrosomal membranes isolated at p60 from wild-type (1/1) mice and Ghr nullizygotes (2/2) using an antiserum against the intracellular
omain of the ;110-kDa GHR protein (seen as a doublet). (f) Western analysis of acid–ethanol serum extracts from p180 wild-type mice (wt), Igf
ullizygotes (negative control), and Ghr nullizygotes using an antibody recognizing IGF1 (;7.5 kDa). The amount of protein loaded on each lane
as extracted from the indicated serum volume (in ml). Human recombinant IGF1 (1 ng) was added to a sample of serum from an Igf1(2/2)
utant as a positive control. (g) Western analysis of unfractionated sera (5 ml per lane) from mice such as those described in (f) using an antibody
hat detects GH (;23 kDa). The amount of GH in wild-type serum (first lane) was below the detection limit of this assay. Purified mouse pituitary
H (1 ng) was added to a sample of wild-type serum (second lane) as a positive control. (h) Examples of semiquantitative RT-PCR analysis of
teady-state Igf1 mRNA (band I) in the liver and lungs of p180 wild-type (wt) and Ghr nullizygous mice (display of amplification products by
outhern blotting; see Materials and Methods). Four animals (two male and two female) of each genotype were examined. Amplification ofb-actin mRNA (band A) was used as a standard.
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146 Lupu et al.1e). Attempts to detect a truncated, soluble form of GHR
resembling GHBP were unsuccessful (see Materials and
Methods). However, any role that this presumptive GHBP-
like molecule could potentially play in the mutants would
be inconsequential (it would affect only the GH ligand that
cannot function in the absence of GHR signaling).
IGF1 and GH assays in Ghr(2/2) mutants. Because
circulating IGF1 is under GH control (reviewed by Scanes
and Daughaday, 1995), we measured serum IGF1 levels in
adult (;6 months of age) Ghr(2/2) mutant and wild-type
mice by a radioimmunoassay (RIA), using as negative con-
trols sera from Igf1 nullizygotes. The results demonstrated
that the IGF1 concentration was 194 6 9 ng/ml in normal
sera, whereas in Igf1(2/2) and Ghr(2/2) mutant sera it was
below the detection limit of the assay (0.4 ng/ml). Consid-
ering that the lowest of three serum dilutions used in these
measurements was 1:50 (see Materials and Methods), we
estimated that the concentration of IGF1 in Ghr(2/2)
mutant serum could not exceed ;10% of the normal value
[(0.4 3 50)/194].
In addition, independent results were obtained by West-
ern analysis using a different antibody (Fig. 1f). Application
of this technique, which is more sensitive than RIA and can
detect at least 0.1 ng of IGF1 per lane, indicated that the
serum level of IGF1 in Ghr(2/2) mutants was closer to
;0.2% of normal. As shown in an example of such assays
(Fig. 1f), using as a positive control recombinant human
IGF1 and as a negative control serum from Igf1 null mice,
IGF1 peptide was undetectable in mutants lacking GHR,
although the amount of acid–ethanol-extractable proteins
from mutant sera that was electrophoresed was 10-fold
higher than that from wild-type specimens (50 vs 5 ml).
Nevertheless, an extremely faint IGF1 signal (barely visible
above background; ;0.1 ng) was detected on occasion in
other assays (not shown) by loading on the gel protein
extracted from 250 ml of mutant serum (0.1 ng/250 ml 5 0.4
ng/ml; 0.4/194 ’ 0.2% of normal). The level of serum IGF1
in a similar Ghr knockout was reportedly 7–10% of normal
(Zhou et al., 1997; Sjo¨gren et al., 2000; Coschigano et al.,
2000) or undetectable (Chandrashekar et al., 1999).
In mice, the physiological mode of GH secretion is
pulsatile in both sexes, although the interval between
pulses is longer in males (;2.5 h vs ,1 h in females;
MacLeod et al., 1991). Therefore, single measurements of
circulating GH, although often reported, are not very infor-
mative. Nevertheless, to demonstrate that a major negative
feedback regulating pituitary GH secretion that is exerted
at both the hypothalamic and the pituitary levels by the
circulating IGF1 (Berelowitz et al., 1981; Tannembaum et
al., 1983; Yamashita and Melmed, 1986) was ablated in both
Ghr and Igf1 null mutants, we assayed GH levels in serum
by Western blotting (Fig. 1g), but did not attempt to derive
accurate quantitative results. Using pituitary GH both as a
positive control and as a size marker, we showed that GH
protein was undetectable in 5 ml of serum from wild-type
mice (the maximum amount that could be loaded on a
lane), whereas serum from Ghr(2/2) or Igf1(2/2) mice (5 G
Copyright © 2001 by Academic Press. All rightml) yielded a strong signal indicating high levels of circulat-
ing GH.
GH-dependent and GH-independent Igf1 expression.
To assess the steady-state level of Igf1 transcripts in various
issues, we performed semiquantitative RT-PCR analysis
sing RNA from wild-type and Ghr(2/2) specimens of
iver, heart, lung, kidney, brain, and reproductive organs
Table 1; examples of the assays are shown in Fig. 1h).
As expected from previous results with lit mutant mice
Mathews et al., 1986; Sugisaki et al., 1993), which main-
ain only ;10% of the normal GH level (Cheng et al., 1983),
e detected a dramatic reduction in the level of Igf1
xpression in Ghr(2/2) mutant liver (;1–2% of the normal
alue). It is known that GH increases hepatic Igf1 gene
xpression at the transcriptional level, as demonstrated by
un-on assays (Mathews et al., 1986).
The practically complete dependence of liver Igf1 tran-
cripts on GH action appears to be unique. In all other
xamined tissues, Igf1 expression, if not GH-insensitive, is
nly partially dependent on GH, as observed in the ovary
nd, in agreement with previous reports (Mathews et al.,
986; Sugisaki et al., 1993), in the kidney (Table 1). In other
ajor organs (heart, lung, testis, uterus; Table 1), Igf1
xpression was found to be GH-independent. The same
bservation was made in the spleen (Mathews et al., 1986)
nd also in the brain (Table 1 and Sugisaki et al., 1993).
hus, a minor negative effect of GH deficiency on brain Igf1
eported previously (Mathews et al., 1986) was not con-
rmed.
GH-independent IGF1 expression was also demonstrated
n some rat tissues, including for example testis (Spiteri-
TABLE 1
Relative Levels of Igf1 Transcripts
Tissue W G Da
Brain 100 6 5.0 108.7 6 6.3 2
Lung 100 6 24.2 87.8 6 4.3 2
Heart 100 6 19.7 99.5 6 20.9 2
Liver 100 6 13.2 2.2 6 1.2 1
idney 100 6 11.2 59.7 6 6.6 1
estis 100 6 13.5 92.6 6 0.5 2
vary 100 6 13.4 29.2 6 4.3 1
terus 100 6 8.7 77.6 6 5.3 2
a The presence (1) or absence (2) of a statistically significant
ifference (D) between wild-type animals (W) and Ghr(2/2) mu-
ants (G) is indicated (Student’s t test; P , 0.05). Mean values 6 SE
expressed as percentages of control levels after normalization; see
aterials and Methods) were calculated from measurements of
our specimens per tissue (two from male and two from female
nimals), except for reproductive tissues (two specimens). The
ean 6 SE (standard error) shown in each case was calculated by
dividing each of the values by the average of the corresponding
wild-type signal (considered 100%) and averaging again the derived
set of percentage values.rech et al., 1991) and skin (Lemmey et al., 1997), whereas
s of reproduction in any form reserved.
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147Growth Control by IGF1 and Growth Hormoneother results were either conflicting between reports or in
disagreement with the mouse data (see Murphy et al., 1987;
Roberts et al., 1987; Hynes et al., 1987; Butler et al., 1994).
According to our evidence, as a direct consequence of
ablation of GH action in Ghr nullizygotes, there is absence
of Igf1 transcripts in the liver correlating with a lack of
immunoreactive IGF1 in serum. Although this correlation
does not prove that hepatocytes are the sole source of IGF1
present in the circulation, it poses the following severe
restriction on the occasionally postulated, but experimen-
tally unsupported and unlikely, extrahepatic origin of cir-
culating IGF1. If in addition to the liver another source
contributing to serum IGF1 exists, expression of Igf1 in this
particular tissue should be GH-dependent.
Scaling. The growth retardation of Ghr(2/2) mutants is
described in a later section. However, because weight does
not necessarily reflect linear growth, we performed a lim-
ited allometric analysis of the relationship between body
lengths (BL) and body weights (BW) measured at different
developmental ages. For this purpose, we used the allomet-
ric scaling equation y 5 a z xb in its logarithmic form
ogy 5 loga 1 blogx, where y is BL, x is BW, b is the slope
f the regression line, and a is the y intercept (see Shea et
l., 1987). In a length vs weight comparison, simple exten-
ion of the regression line of a dwarf mutant by the
orresponding line of the wild-type control indicates an
sometric relationship (common trajectory of relative
rowth) with a predicted slope of 0.33 (lack of allometric
caling and no change in proportion). This was almost
xactly what our analysis showed (Fig. 2a), as the results of
egression analysis for the wild-type and Ghr(2/2) mice
ere BL 5 3.42 z BW0.326 (coefficient of correlation r 5 0.99),
ndicating that the mutants are normally proportioned.
FIG. 2. Allometric plots. (a) Log–log plot and first-order regressio
s corresponding weights determined at 18, 25, 31, 45, and 60 days
nd of the epiphyseal (TE) and diaphyseal (TD) widths of the tibia
orresponding regression analyses were TL 5 2.8BL 0.8, TE 5 0.3B
ases indicates an isometric relationship.nterestingly, in a similar comparison between wild-type
Copyright © 2001 by Academic Press. All rightnd transgenic mice overexpressing GH, it was found that
he nose-to-rump length exhibited an isometric relation-
hip to body weight in both groups of animals (Shea et al.,
987).
We also observed that the weights of major organs deter-
ined at 1 and 3 months of age were reduced in the
hr(2/2) mutants proportionate to body weights in com-
arison with wild-type controls, with the exception of the
rain and kidney and also the spleen in the older animals
Table 2). The kidney and spleen were disproportionately
educed in size, whereas the brain/body weight ratio was
elatively increased by 70% in p30 mutants. Most likely,
his difference is due to the fact that brain growth is
ractically completed by the time GH action commences in
ice (see Winick and Grant, 1968; Bishop and Wahlsten,
999). Thus, although the normal brain to body weight ratio
ecomes relatively smaller as growth proceeds (negatively
llometric relationship), this ratio is higher in Ghr(2/2)
utants in comparison with wild-type controls because of
heir growth retardation (smaller denominator).
Despite deviations from isometric scaling in particular
rgans, the dwarfism of mice lacking GHR is almost ateliotic
proportionate). This observation, in conjunction with the
revious conclusion that the GH control of IGF1 expression
aries between extrahepatic tissues and may be partial or
bsent, suggests strongly that the magnitude of this depen-
ence, wherever it occurs, is small. Otherwise, significantly
egative allometric relationships with different severities of
mpact between organs would have been observed.
Comparison of Growth Retardation Phenotypes
Genetic crosses and growth curves. To investigate ge-
the body lengths of wild-type (W) and Ghr(2/2) mutant (G) mice
ge. For further details, see text. (b) Log–log plots of the length (TL)
ody length (BL) at p130 (see data in Table 3). The results of the
nd TD 5 0.07BL1 .1 (r . 0.99). A slope of 1.0 or close to 1.0 in alln of
of a
vs b
L
1.0, anetically the relationship between GH and IGF1 in postna-
s of reproduction in any form reserved.
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148 Lupu et al.tal growth, we intercrossed Ghr(1/2)/Igf1(1/2) double
heterozygotes and also crossed to a lesser extent such
heterozygotes with Ghr(2/2)/Igf(1/2) partners. We then
compared progeny that we considered indiscriminately as
phenotypically “normal” (i.e., wild-type or heterozygous
animals for either or both of the Ghr and Igf1 genes; “W”
phenotype) with single mutants lacking either GHR (“G”
mutant phenotype) or IGF1 (“I” mutant phenotype) or both
TABLE 2
Comparison of Organ Weights between Wild-Type and Ghr(2/2) M
p30
Organ
Weight (mg)
% Body weight
(% of control)a
W G W G
(A
Brain 405.4 6 12.0 375.6 6 9.1 2.00 6 0.13 3.46 6 0.15
(100 6 6.99) (170 6 7.2)
Thymus 86.3 6 4.5 54.2 6 5.9 0.42 6 0.04 0.49 6 0.03
(100 6 8.8) (116.2 6 6.4)
Heart 103.3 6 4.5 61.2 6 3.5 0.50 6 0.01 0.56 6 0.01
(100 6 2.9) (112.6 6 2.5)
ungs 278.5 6 19.4 154.3 6 16.4 1.34 6 0.06 1.41 6 0.13
(100 6 4.5) (105.3 6 9.5)
iver 945.3 6 35.9 503.9 6 74.5 4.59 6 0.29 4.57 6 0.51
(100 6 6.3) (99.6 6 11.2)
Spleen 81.1 6 3.8 36.1 6 6.2 0.39 6 0.02 0.33 6 0.04
(100 6 6.2) (83.6 6 10.8)
Kidneys 317.0 6 18.2 134.1 6 10.1 1.52 6 0.04 1.23 6 0.06
(100 6 2.4) (80.7 6 3.8)
Testes 154.6 6 10.2 71.3 6 9.9 0.75 6 0.04 0.66 6 0.1
(100 6 5.6) (87.7 6 13)
Body (g) 20.8 6 1.1 10.9 6 0.6
n 6 4
(B)
Brain 406.9 6 17.8 387.3 6 7.8 2.45 6 0.11 4.00 6 0.34
(100 6 4.4) (163.2 6 14)
Thymus 75.5 6 5.9 54.1 6 8.2 (0.45 6 0.02 0.55 6 0.07
(100 6 4.9) (121.2 6 16.7)
Heart 86.4 6 4.3 53.9 6 1.9 0.52 6 0.01 0.55 6 0.03
(100 6 4.1) (98.4 6 2.7)
Lungs 247.4 6 2.6 136.0 6 11.7 1.50 6 0.05 1.42 6 0.22
(100 6 3.5) (94.9 6 14.7)
Liver 838.0 6 62.0 446.0 6 70.2 5.04 6 0.34 4.51 6 0.69
(100 6 6.8) (89.5 6 13.7)
Spleen 58.1 6 7.1 26.3 6 5.4 0.35 6 0.03 0.27 6 0.06
(100 6 9.9) (76.7 6 17.0)
Kidneys 239.9 6 14.4 115.1 6 11.7 1.44 6 0.06 1.16 6 0.07
(100 6 3.8) (80.7 6 4.9)
Ovaries 4.3 6 0.7 2.6 6 0.6 0.03 6 0.004 0.03 6 0.006
(100 6 5.6) (87.7 6 13)
Body (g) 20.8 6 1.1 10.9 6 0.6
n 5 4
a Relative (% of control) values 6 SE shown in parentheses were
then compared to evaluate statistically significant differences (D; s
shown.(double-mutant phenotype; “D”).
Copyright © 2001 by Academic Press. All rightIn our growth analysis, we determined body weights for a
period of ;6 months, but analyzed extensively and present
here the most robust portion of our dataset up to p100, a
time at which the growth of mice approached closely a
steady state (growth plateau). Although this phase differs
between mouse strains (it occurs, for example, at ;p170 in
DBA/2 mice; Goedbloed, 1975), it was attained at ;p130 in
the animals that we examined, similar to ICR mice (Silber-
p90
Weight (mg)
% Body weight
(% of control)
DW G W G
s
453.5 6 5.9 361.8 6 10.4 1.59 6 0.04 2.13 6 0.15
(100 6 2.8) (133.9 6 9.3) 1
49.4 6 4.9 33.4 6 4.6 0.17 6 0.01 0.19 6 0.01
(100 6 7.3) (112.7 6 8.3) 2
121.6 6 3.2 59.1 6 5.3 0.43 6 0.01 0.35 6 0.03
(100 6 2.3) (80.4 6 7.5) 2
239.5 6 15.2 152.4 6 19 0.84 6 0.05 0.87 6 0.05
(100 6 5.6) (104.2 6 5.8) 2
1234.6 6 144 565.4 6 61.6 4.37 6 0.63 3.28 6 0.29
(100 6 14.5) (75.1 6 6.7) 2
61.9 6 3.4 24.8 6 2.2 0.22 6 0.01 0.14 6 0.01
(100 6 6.7) (65.1 6 2.3) 1
434.8 6 28.8 174.7 6 12.3 1.52 6 0.06 1.02 6 0.07
(100 6 4.3) (67.2 6 4.8) 1
229.9 6 12.9 118.1 6 5.4 0.8 6 0.02 0.7 6 0.06
(100 6 2.8) (99.4 6 8.2) 2
28.6 6 1.1 17.3 6 1.4
4 4
les
422.9 6 18.4 391.9 6 16.0 1.84 6 0.02 2.57 6 0.03
(100 6 1.2) (139.9 6 15) 1
56.4 6 4.6 44.3 6 3.5 0.24 6 0.01 0.29 6 0.03
(100 6 5.6) (120.2 6 13) 2
104.8 6 4.2 64.0 6 6.8 0.46 6 0.01 0.41 6 0.02
(100 6 1.2) (88.6 6 4.8) 2
261.3 6 13.3 144.4 6 20.5 1.14 6 0.07 0.91 6 0.04
(100 6 6.3) (79.5 6 3.8) 2
1115.0 6 77.7 927.5 6 126 4.88 6 0.4 5.82 6 0.14
(100 6 8.1) (119.2 6 2.8) 2
93.4 6 15.2 42.1 6 7.6 0.4 6 0.05 0.26 6 0.03
(100 6 13.1) (66.1 6 8.5) 1
285.8 6 18.9 173.5 6 28.1 1.24 6 0.06 1.08 6 0.11
(100 6 9.6) (87.3 6 8.6) 1
9.2 6 0.6 6.4 6 1.2 0.04 6 0.001 0.04 6 0.004
(100 6 2.8) (99.4 6 8.2) 2
28.6 6 1.1 17.3 6 1.4
4 4
ved by the same procedure described in the legend to Table 1 and
ble 1). Averages were calculated from the numbers (n) of animalsice
D
) Male
1
2
2
2
2
2
1
2
Fema
1
2
2
2
2
2
1
2
deri
ee Tamann and Kedar, 1977).
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149Growth Control by IGF1 and Growth HormoneThe rate and duration of proliferation, which determines
the growth process, is reflected in the progressive increase
in weight until a complete balance between proliferative
and apoptotic events is attained. Thus, relative growth
patterns of wild-type and mutant mice can be compared
from plots of weight versus developmental age (growth
curves), which together with their derivatives (plots of
growth rates) provide an overall informative, albeit coarse
index of the growth process. It should not escape attention,
however, that the conclusions from such comparisons are
indicative, rather than absolute descriptions, of growth
patterns because, even if experimental inaccuracies in mea-
surements are ignored, there is considerable variability in
weights within and between litters of mice at any postnatal
age (in contrast to the significantly narrower weight ranges
during embryogenesis). In part, this variability is due to
environmental factors, including nutrition. Therefore, re-
gression analyses become necessary, a fact emphasizing
further that, conceptually, any generalizations derived from
descriptions of postnatal growth have mainly a statistical
character.
From a comparison of growth curves (Figs. 3a and 3b),
which were derived by appropriate treatment of primary
weight data (see Materials and Methods), a difference be-
tween sexes in the weights of wild-type controls (heavier
males) was evident from ;p20 onward, as expected (see, for
xample, Goedbloed, 1974; Koops et al., 1987). This gender
difference is due to the emerging actions of distinct gonadal
steroids resulting, for example, in sexually dimorphic pat-
terns of pulsatility in pituitary GH secretion commencing
at ;p20 (see Davey et al., 1999). Interestingly, sex-
ependent weight differences were not detectable in mu-
ants lacking IGF1 or in double mutants. On the other hand,
emale animals lacking GHR tended to be somewhat
eavier than the corresponding males, but this difference
as not statistically significant. Thus, for regression anal-
sis (Fig. 3b), the data for each mutant phenotype were
umped, regardless of sex, to increase the number of obser-
ations (Fig. 3a). This was necessary because of the wide
ange of recorded values, apparently due to segregation of
resumptive modifiers affecting the weights of progeny
rom matings of animals with mixed genetic backgrounds
see Materials and Methods). Due to the nature of this
nalysis, minor effects of haploinsufficiency (reported to be
10% with a similar Ghr knockout; Coschigano et al.,
000) would have been invisible and were ignored.
Independent and overlapping IGF1 and GH functions.
n contrast to the neonatal dwarfism of I mutants (Liu et al.,
993; Baker et al., 1993), the birth weight of G mutants was
ormal. Prior to p10, there was no statistically significant
ifference in body weight between W mice and G mutants
r between I and D mutants (P . 0.05; t test). After 2
ostnatal weeks, however, and at later times, our compari-
ons showed clearly that all mutants were growth-retarded
n the order G . I . D (Figs. 3b and 4a).
If all of the GH actions, as reflected in whole body weight,
ere mediated by IGF1, the expectation was that the c
Copyright © 2001 by Academic Press. All righthenotype of the double mutants would be indistinguish-
ble from that of Igf1 nullizygotes. This is clearly not the
ase. Therefore, in terms of growth physiology, the GH and
GF1 signaling pathways serve both independent and over-
apping functions. (Any IGF1-mediated GH action is de-
ned here as a functional overlap.) To our knowledge, this
s the first time that this conclusion can be reached defini-
ively on the basis of genetic evidence.
Interestingly, when absolute growth rates were compared
Fig. 3c), it became obvious that the temporary decline in
ormal rate, which is always observed in wild-type mice
hortly after weaning and prior to a growth spurt, coincided
ith the negative growth rate seen in all mutants. More-
ver, the spurt in wild-type mice corresponded to mutant
atch-up growth compensating for the previous weight loss.
hese observations suggest that the mechanism responsible
or these rate shifts is probably common between W and
utant mice. Although this mechanism remains unknown,
t is thought that it is not due to weaning per se (discussed
y Boettiger and Osborn, 1938; Koops et al., 1987).
When attained weight was used as a normalizing factor to
ransform absolute rates to specific growth rates (Fig. 3d), it
as clearly seen that the latter became practically indistin-
uishable between genotypes (except for a minor deviation
f I mutants) at around p40. In fact, the specific rates had
eclined considerably and tended toward zero (i.e., the
rowth of wild-type and mutant mice was approaching a
teady state). Because growth at any time point is a function
f growth already attained, the equalization of specific
rowth rates reveals that the separate and concerted actions
f GH and IGF1 are postnatally important mainly between
5 and 40 days of mouse age.
Relative contributions of GH and IGF1 signaling to
rowth. To assess the magnitude of the independent and
verlapping GH and IGF1 contributions to growth, we
erived some rough estimates (Figs. 3e and 3f), according to
he following considerations.
At each time point, the weight Dw of double mutants is
he result of growth controlled by mechanisms unrelated to
he GH/IGF1 axis (i.e., “basal weight,” in regard to the GH
nd IGF1 actions). Therefore, if the wild-type weight is Ww,
he relative contribution b of basal weight to the total body
weight is b 5 Dw/Ww. In each of the single mutants, there
s no overlapping GH/IGF1 function. Therefore, after sub-
raction of the basal weight Dw from the weight Gw of the
mutant lacking GHR, but retaining IGF1, the remainder is
the contribution of IGF1. Then, the relative contribution i
of IGF1 to body weight is i 5 (Gw 2 Dw)/Ww. In an
analogous calculation, the relative contribution g of GH
signaling in the mutants with weight Iw (lacking IGF1, but
retaining GHR function) is g 5 (Iw 2 Dw)/Ww. The relative
contribution o of GH/IGF1 overlapping function is then o 5
2 g 2 i 2 b. The same quantity (o) can also be calculated
from the relationships (Ww 2 Gw)/Ww 5 g 1 o and (Ww 2
Iw)/Ww 5 I 1 o. Relative weights expressed as percentages
f normal weight (%N) are derived by multiplying the
alculated ratios by 100 (see Figs. 3e and 3f).
s of reproduction in any form reserved.
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150 Lupu et al.On the basis of these considerations we have estimated
that at steady state ;17% of body weight has been attained
by growth processes unrelated to the GH/IGF1 axis, that
IGF1 makes by itself a more significant contribution than
FIG. 3. Growth analysis. (a) Average growth curves of male (Wm) a
I), or both (D) were derived as described under Materials and Met
he number of animals of each phenotype used for determination o
n (b) after regression. From the data in (b), absolute growth rates (d
are shown in (c) and (d), respectively. Each curve point in (c) represe
whereas each point in (d) is the corresponding point in (c) divided by
“% daily weight gain”). The data in (b) were also used to calculate
estimates of the contributions to total body weight of the GH fun
GH/IGF1 function (o), as shown in (e) and (f). The relative weight
rowth systems unrelated to the GH/IGF1 axis. For details of theGH acting alone (35% vs 14%), and that the overlapping e
Copyright © 2001 by Academic Press. All rightH/IGF1 function makes a major contribution to total
eight (34%). However, we emphasize again that these
stimates are simply indicative of a growth pattern and are
resented here exclusively for illustration purposes, as the
male (Wf) normal animals and of mutants lacking GHR (G), IGF1
(the method of analysis precludes the presentation of error flags).
ights is shown in parentheses. The same growth curves are shown
t) and specific growth rates [(dW/dt) 3 (1/W)] were calculated and
he difference of weights at 2 consecutive days (weight gain; g/day),
average of the two weights (this ratio multiplied by 100 represents
ive weights (%N) for each mutant and to derive from these values
alone ( g), of the IGF1 function alone (i), and of the overlapping
e double mutant (“basal weight”; b) represents the contribution of
lations, see text.nd fe
hods
f we
W/d
nts t
the
relat
ction
of thxact magnitude of relative values will change by using, for
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151Growth Control by IGF1 and Growth HormoneFIG. 4. (a) Example of p60 body size phenotypes of wild-type mice (W) and mutants lacking GHR (G), IGF1 (I), or both (D). (b) Tibiae from
130 mice of the same phenotypes as in (a). (c–h) Longitudinal sections of the proximal tibial epiphysis at p5 (c), p10 (d), p15 (e), p22 (f), p30
g), and p130 (h) from mice of the indicated phenotypes. (i) Sagittal sections through the patella of the same mice as in (h). Arrowheads in
c) and (d) indicate invading vascular buds of the secondary ossification center (oc). At p10 (d), the boundaries of the growth plate (gp) are
learly defined in the wild type. Arrows in (f–h) indicate proliferative chondrocytes (pc), hypertrophic chondrocytes (hc), and ossified bone
ob). All specimens of the same age are displayed at the same magnification. The scale bar (shown once for each set of images) corresponds
o 200 mm in (c–h) and to 50 mm in (i). For details, see text.
Copyright © 2001 by Academic Press. All rights of reproduction in any form reserved.
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152 Lupu et al.example, as wild-type weight that of female animals or by
repeating the growth analyses in different genetic back-
grounds. Regardless of actual levels, however, the graph
with estimates of relative contributions (Fig. 3f) is still
another pictorial representation of the important conclu-
sion that after ;p40 the contribution of the GH/IGF1
system to growth is practically finished.
IGF1 and GH are key components of growth control
pathways. Genes controlling growth are members of
athways serving (directly or indirectly) short- and long-
ange circuits of signaling interactions (autocrine/paracrine
nd systemic actions, respectively) that ultimately affect
he performance of the cell cycle (discussed by Efstratiadis,
998). In this regard, it can be firmly concluded from the
valuation of our genetic data (permitting the establish-
ent of causal relationships) that, at least in rodents, the
athway in which the GH/IGF1 axis participates provides
he main conduit of growth control. Additional unrelated
rowth control systems apparently exist, but they play
elatively minor roles, since only ;17% of the total body
size of an adult mouse can be attained without the partici-
pation of GH and IGF1. This value approaches the appar-
ently lowest limit that is evolutionarily tolerable for mam-
malian body size, as a double Ghr/Igf1 mutant does not
exceed ;5 g in weight, which is the same as that of the
smallest bat Pipistrellus pipistrellus and only twice the size
of the smallest known mammal, the shrew Suncus etruscus
(see Ju¨rgens et al., 1981). It should be noted that, from the
oint of view of IGF functions, the basal weight value of
7%N is an overestimate, because the IGF2 contribution to
mbryonic growth has not been taken into account in the
alculations presented above. Importantly, in terms of
rowth control, there is no opportunistic compensation by
GF2 in the absence of IGF1 and vice versa (Baker et al.,
993), so that mutants lacking both of these ligands are
0%N at birth. As these double Igf1/Igf2 null mutants are
ot viable, it is impossible to determine the relative,
teady-state body size of triple mutants also lacking GH. It
an be safely hypothesized, however, that this size would
ave been ,17%N.
On the basis of our analysis, we surmise that, with the
xception of a basal machinery sustaining minimal growth,
ll other growth control genes must be members of the
ircuitry involving GH/IGF1 signaling because, although
hey remain intact, they cannot compensate for the growth
etardation of D mutants. The identities of such genes are
rogressively being revealed by knockout experiments.
ome of these results confirm more or less predictable
elationships between the disrupted genes and GH/IGF1
unctions. For example, GH-stimulated GHR dimerizes and
ctivates JAK2, which (among other effectors) phosphory-
ates STAT5b, a transcription factor activating the Igf1 gene
promoter acting either alone or synergistically with HNF1a
(see Meto´n et al., 1999; Herrington et al., 2000). It was not
urprising, therefore, that knockouts of the genes Stat5b
Udy et al., 1997; Teglund et al., 1998) and Hnf1a (Lee et al.,
998) resulted in dwarfism associated with low serum IGF1.
Copyright © 2001 by Academic Press. All rightn other cases, however, unsuspected relationships of gene
unctions with IGF1-mediated growth control were ob-
erved. Such examples include transgenic overexpression of
L-6 (De Benedetti et al., 1997) and knockouts of the genes
rf1 (encoding a ras guanine nucleotide exchange factor;
tier et al., 1998), Emk (encoding ELKL motif kinase, a
ember of a small family of Ser/Thr protein kinases;
essone et al., 1999), and Src3 (encoding a steroid receptor
oactivator; Xu et al., 2000). Moreover, it appears that even
he thyroid hormone participation in growth (reviewed by
illiams et al., 1998) involves the GH/IGF1 axis (see Go¨the
t al., 1999).
Is there an endocrine IGF1 function? Effective IGF1
ction within an early window of developmental time
rovides a plausible interpretation of the results in two
eports describing liver-specific, conditional knockouts of
he Igf1 gene using the cre/loxP system (Sjo¨gren et al., 1999;
akar et al., 1999). In both cases, the apparently unaffected
verage body weights of conditional mutants exhibiting
ignificantly reduced levels of serum IGF1 were interpreted
s demonstrating lack of participation of the circulating
actor in growth promotion. However, ablation of endocrine
GF1 was incomplete and occurred only postnatally and
elatively late, long after the aforementioned critical post-
eaning period of growth spurt. It is likely that, as in
nalogous cases (see Postic and Magnuson, 2000), cre-
ediated DNA excision was progressive in the population
f hepatocytes, consistent with the observation that serum
GF1 was ;50%N at p26 and 23%N at p42 (Yakar et al.,
999) or 25.4%N at p77 (Sjo¨gren et al., 1999). The presence
f this residual circulating IGF1 was attributed to an
nknown extrahepatic source, but this is an unlikely pos-
ibility. We think that, at least at present, the view that
GF1 participates in growth control in part by an endocrine
unction is still viable.
Bone Development in Mutants
Overview. To complement our study on growth based
on weight analysis, we aimed to provide some information
on linear growth by examining skeletal development. Spe-
cifically, we focused our study on long bones, a system in
which the GH/IGF1 relationship has been studied exten-
sively (reviewed by Ohlsson et al., 1998). In this regard, we
have examined in detail the proximal growth plate of the
tibia, considered widely as a representative of long bone
development (see, for example, Walker and Kember,
1972a,b). Consistent with this notion, we have observed
that the tibial dimensions (length and width of the diaphy-
sis and the epiphysis measured at fixed levels) retain iso-
metric relationships to body length in both mutants and
wild-type controls (Fig. 2b). We note that the relative body
size relationships W . G . I . D were maintained in
terms of tibia dimensions (Fig. 4b and Table 3), but the
differences between G and I mutants were marginal (dis-
cussed in a later section).Because mutants lacking GHR do not differ in external
s of reproduction in any form reserved.
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153Growth Control by IGF1 and Growth Hormonephenotype from wild-type mice until p15, we compared
only W and I mice at early postnatal ages (p5–p15; Figs.
c–4e) and began comparing all four phenotypes at p22 and
ther more advanced ages (Figs. 4f–4i). From these analyses,
e conclude that the Igf1 and Ghr mutations or their
combination does not result in histologically dysmorphic or
disorganized skeletogenic tissues (absence of histopatho-
logical changes). In fact, all of our morphological observa-
tions can be interpreted as indicative of developmental
delays due to hypoproliferation, in combination with a
reduced size of hypertrophic chondrocytes. Below, we
TABLE 3
Morphometric Data
W
Body length (cm)
p22 7.79 6 0.07 (9)
p130 10.25 6 0.20 (8)
ibia length (mm)
p22 14.33 6 0.11 (9)
p30 16.72 6 0.27 (5)
p100 18.37 6 0.09 (3)
p130 18.28 6 0.13 (9)
Tibia width (mm; p130)
Epiphysis 3.04 6 0.07 (9)
Diaphysis 0.96 6 0.047 (9)
Growth plate (proximal tibia; p22)
Total height (mm) 314.8 6 12.0
“RZ” height (mm) 22.3
PZ height (mm) [A] 120.2 6 7.4
PZ cell number
(column) [B]
17.8 6 0.3
PZ: 1-cell height [A/B] 6.75
HZ height (mm) [C] 172.3 6 10.6
HZ cell number
(column) [D]
7.8 6 0.2
HZ: 1-cell height [C/D] 22.1
HZ cell number in 0.024 mm2 48.2 6 1.6
HZ: 1-cell area (mm2) 496.3 6 16.7
HZ last cell (mm) 32.7 6 0.3
BrdU (%; PZ) 18.7 6 0.6
Growth plate (proximal tibia; p30)
Total height (mm) 242.3 6 20.7
“RZ” height (mm) 6.9
PZ height (mm) 106.7 6 7.4
PZ cell number 17.9 6 0.9
HZ height (mm) 128.7 6 9.6
HZ cell number 6.3 6 0.2
Note. The length and width dimensions represent mean 6 SE val
total height of each growth plate represents the distance betwee
proliferative (PZ), and hypertrophic (HZ) zones were measured as de
growth plate parameter measured, 4 animals were analyzed for eac
and Ghr and Igf1 null mutants) or 2 (double mutants). Seven mea
measurements per animal). To provide an estimate for the average si
counted in a fixed area of 23,831 mm2.present the evidence supporting these conclusions. b
Copyright © 2001 by Academic Press. All rightDelayed development of secondary ossification centers.
ong bones grow in length by endochondral ossification (a
emplate of cartilage formed from mesenchyme is replaced
y bone; Cancedda et al., 1995). Increase in length occurs by
one formation on the diaphyseal side of the growth plate
Hunziker, 1994). Chondrocytes in this cartilaginous disc
located between each semispherical epiphysis and the
ylindrical diaphysis) proliferate, forming characteristic
olumns with spatial polarity toward the diaphyseal side
Abad et al., 1999), and then differentiate, becoming hyper-
rophic and laying down calcifying cartilaginous matrix,
G I D
5 6 0.08 (6) 5.10 6 0.07 (4) 4.10 6 0.10 (3)
7 6 0.10 (9) 6.77 6 0.17 (3) 4.43 6 0.13 (3)
6 6 0.16 (10) 9.53 6 0.21 (4) 8.00 6 0.26 (3)
4 6 0.20 (5) 11.25 6 0.05 (2) 9.3 (1)
3 6 0.20 (3) 12.80 6 0.26 (3)
0 6 0.14 (9) 12.95 6 0.13 (6) 9.32 6 0.14 (6)
0 6 0.05 (9) 2.07 6 0.05 (6) 1.33 6 0.11 (6)
1 6 0.019 (9) 0.55 6 0.019 (6) 0.37 6 0.021 (6)
6 11.7 246.2 6 6.7 233.5 6 12.1
30.2 51.4 69.3
6 6.6 90.3 6 8.3 70.7 6 6.9
6 0.6 13.4 6 0.4 10.6 6 0.3
6.4 6.74 6.67
6 10.8 104.5 6 1.4 93.5 6 4.6
6 0.3 6.7 6 0.1 6.5 6 0.1
16.28 15.6 14.38
6 1.9 75.4 6 1.2 77.0 6 3.4
6 9.1 316.3 6 5.0 311.6 6 14.7
6 0.2 26.6 6 0.6 24.7 6 0.3
6 0.9 11.7 6 0.8 8.02 6 0.2
6 9.7 184.5 6 7.7 171.4 6 4.7
25.5 37.1 51.8
6 4.8 73.0 6 1.8 57.3 6 1.5
6 0.2 13.9 6 0.2 10.2 6 0.4
6 4.5 74.4 6 0.8 62.3 6 3.9
6 0.1 5.4 6 0.2 5.3 6 0.2
averaged from the numbers of animals shown in parentheses). The
o chondrosseous junctions. The heights of the “resting” (“RZ”),
ed under Materials and Methods. To derive average values for each
notype at p22, whereas at p30, the number was 3 (wild-type mice
ents were taken per section, using three sections per animal (21
a hypertrophic chondrocyte for each phenotype, cell numbers were6.4
7.3
12.1
13.5
13.6
13.9
2.3
0.6
231.4
88.9
13.9
112.3
6.9
71.5
334.0
25.8
11.8
184.0
72.9
12.9
85.6
5.4
ues (
n tw
scrib
h phe
surem
ze ofefore undergoing apoptosis (Gibson, 1998; Horton et al.,
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154 Lupu et al.1998). Vessels invading the cartilage bring with them
perivascular mesenchymal cells, some of which are osteo-
blasts that deposit bone matrix on the calcified cartilagi-
nous template forming metaphyseal trabecular bone (pri-
mary spongiosa). The capillaries and osteoblasts that are the
first to invade constitute an ossification center. This pro-
cess continues until epiphyseal closure (fusion between the
epiphysis and the diaphysis), although, in contrast to hu-
mans, this state is approached, but apparently not com-
pleted in particular rodent growth plates, including that of
the proximal tibia (see Dawson, 1935; Walker and Kember,
1972b).
The same ossification steps take place in the epiphysis
FIG. 5. (a) Histological comparison at high magnification of growt
utant phenotypes at p30 (see Fig. 3g), to display in detail the redu
roliferative zone; HZ, hypertrophic zone; see also Table 3) and of t
ndicated with yellow horizontal bars (considering the upper limit
he primary spongiosa). (b) BrdU labeling of chondrocytes in the grow
henotypes at p22). The staining appears as dark blue. There are cl
c) BrdU labeling of stromal cells in the primary spongiosa [specime
n the mutants. All scale bars correspond to 50 mm.itself, but in this case the chondrocytes, which are solitary c
Copyright © 2001 by Academic Press. All rightr present in small clusters rather than being arranged in
olumns, differentiate from flat proliferating cells at the
eriphery of the cartilage to enlarged hypertrophic cells
oward the center. Thus, ossification in this region spreads
rom a secondary ossification center radially, whereas the
arlier ossification in the diaphysis spreads from a primary
enter proximally and distally in a cylinder forming a bone
arrow cavity.
The first appearance of secondary ossification centers in a
articular bone occurs always postnatally, but the time
aries widely between mouse strains (see, for example,
ohnson, 1933; Wirtschafter, 1960; Floyd et al., 1987; Patton
nd Kaufman, 1995). Initially, the population of cells in the
tes and their adjacent regions between the indicated wild-type and
in the mutant specimens of the height of chondrocyte zones (PZ,
rimary spongiosa (PS). The approximate borders between zones are
e darkly staining round cells of the bone marrow as the bottom of
lates of the proximal tibia (specimens from mice with the indicated
fewer labeled chondrocytes in the mutants (see text and Table 3).
in (b)] indicating that there is also hypoproliferation of osteoblastsh pla
ction
he p
of th
th p
early
ns asartilaginous epiphysis is morphologically quite homoge-
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155Growth Control by IGF1 and Growth Hormoneneous and a demarcation between epiphyseal and growth
plate chondrocytes is not discernible. However, lineage
specification has probably already occurred, according to a
model postulating two distinct endochondral ossification
processes (Vu et al., 1998): one occurring in growth plate
chondrocytes, expressing for example Ihh (Iwasaki et al.,
1997), and a different one in epiphyseal chondrocytes that
remain Ihh-negative.
At the earliest time point that we have examined (p5), we
observed that, in both wild-type controls and Igf1 nullizy-
gotes, columns of chondrocytes present in the presumptive
region of the developing growth plate could already be
discriminated from epiphyseal chondrocytes. Still, the
epiphysis was entirely cartilaginous and characterized by
invading vascular buds signifying the initiation of forma-
tion of a secondary ossification center (Fig. 4c, arrowheads).
The bud in the Igf1 mutant, however, was barely detectable
in comparison with that in the wild-type control that had
reached a more advanced stage.
FIG. 6. In situ hybridization analysis of gene expression in proxim
In all four phenotypes, transcripts for the examined collagen types
may be some variability in signal intensity (dark staining). The
measurements in Table 3. (d) In wild-type mice (W), hybridiz
proliferative chondrocytes with an antisense (AS) but not with a (co
because they continue to express a modified transcript (Figs. 1c an
proliferative and hypertrophic chondrocytes in both wild-type and G
hr null mice and Igf1 antisense probe for Igf1 null mice) did notFive days later (p10), the formation of the secondary p
Copyright © 2001 by Academic Press. All rightssification center had progressed significantly in the con-
rol, whereas in a corresponding Igf1 null specimen, despite
ome advancement, only two small ossifying regions were
iscernible (Fig. 4d, arrowheads). At p15 (Fig. 4e), notwith-
tanding further progress of the ossification process in the
gf1 mutant, the delay in the formation of the secondary
ssification center exceeded 5 days, as the development of
his structure had not yet reached the stage that the control
pecimen had attained at p10. Additional comments about
he development of secondary ossification centers in all of
he mutants are made below in the context of a comparison
f epiphyseal bone formation.
Histological analyses of growth plates. Classically,
hree zones of chondrocytes (occasionally with further
ubdivisions) are described in the growth plate: resting
germinal or reserve), proliferative, and hypertrophic. The
ather flat chondrocytes in the proliferative zone divide
ctively and their spatial organization in columns repre-
ents the temporal progression of an ordered differentiation
bia sections at p22. The probes used are indicated at the top. (a–c)
, and I) are expressed in appropriate types of cells, although there
ness of the layers expressing these markers correlates with the
signal signifying Ghr expression is detected unequivocally in
l) sense (S) probe. Ghr null mice were not used as negative controls
). (e) Igf1 gene expression was detected with an antisense probe in
ull mice. The negative controls (Igf1 sense probe for wild-type and
staining. All scale bars correspond to 50 mm.al ti
(II, X
thick
ation
ntro
d 1d
hr nrocess, as they pass through well-defined stages character-
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156 Lupu et al.ized by changes in shape and size and deposition of extra-
cellular matrix components. More distally, toward the
diaphyseal border of the growth plate, cells become more
spherical and increase in size prior to their death at the
cartilage/bone junction. Although this process is univer-
sally referred to as “hypertrophy,” it does not appear to be a
true increase in cellular constituents, but is rather a swell-
ing due to an increase in water content by an unknown
mechanism, potentially accompanied by cytoskeletal rear-
rangements (see Farquharson et al., 1999).
In contrast to proliferative and hypertrophic cells, we
think that the identity and role of resting chondrocytes
remain an open issue (see also Price et al., 1994; Nuttall et
l., 1999; Bailo´n-Plaza et al., 1999). This cell population has
een described quite often as including at least a subset of
resumptive stem cells (see Kember, 1971, 1978; Buck-
alter et al., 1985; Hunziker, 1994), but to our knowledge
o criteria or markers allowing their identification were
ver assigned and, despite some attempts (see, for example,
hlsson et al., 1992), no hard evidence was ever presented
o demonstrate that resting cells are the immediate precur-
ors of proliferative chondrocytes. In fact, the resting zone
s defined only morphologically as a population of mostly
olitary cells occupying the space between the bone being
ormed in the secondary ossification center and the zone of
roliferative chondrocytes (columns). Accordingly, as the
econdary ossification center expands, the resting zone is
ontinuously shrinking, so that it is impossible to make a
istinction between resting chondrocytes and the epiphy-
eal cartilaginous elements at the moving front of the
orming bone toward the growth plate. Thus, if a develop-
ental delay occurs, as is the case with G, I, and D
mutants, the resting zone, recognized exclusively on the
basis of histological position, will appear as enlarged. This
could be quite misleading. For example, a comparison of
growth plates between normal and Igf1 null mice (Wang et
al., 1999) led, in our opinion, to the unfounded interpreta-
tion that there is an expansion of the resting zone in the
mutants as a consequence of enhanced GH activity due to
the absence of IGF1 and elimination of the negative feed-
back in GH secretion. At present, we prefer to maintain an
agnostic position and have avoided interpretations in regard
to the resting zone, which we have defined as the remainder
after subtracting from the height of the growth plate (dis-
tance between the two chondrosseous junctions) the sum of
the heights of the proliferative and hypertrophic zones
(Table 3).
Comparison of histological sections of the proximal tibia
regions between W, G, I, and D mice at p22 and p30
revealed that both the proliferative and the hypertrophic
zones of chondrocytes were shorter in the mutants in the
same order as for lengths and weights (W . G . I . D;
Table 3 and Fig. 5a). The average height of the proliferative
zone in each of the phenotypes was found to be proportional
to cell number. Therefore, proliferative cell size was normal
in all three mutants (Table 3; compare A/B ratios at p22;
average cell height of 6.64 6 0.08 mm). In contrast, the c
Copyright © 2001 by Academic Press. All rightaverage height of a hypertrophic chondrocyte in the mu-
tants (same for all;15.4 6 0.55 mm; see C/D ratios, Table 3),
was only ;70% of the corresponding dimension in the
controls (22.1 mm). A similar ratio (;65%) was calculated
from the results of counting hypertrophic cell numbers in a
fixed area of known dimensions (Table 3). Although the
mechanism resulting in this alteration is unknown, this is
the only observation that can be interpreted as suggesting
that the GH/IGF system may be involved not only in
proliferative events but also in differentiation of chondro-
cytes toward a hypertrophic state.
Overall, our observations allow the following interpreta-
tion concerning the reduction of bone length in the mu-
tants. The rate of longitudinal bone growth is considered to
be a function of the rate of proliferation in the columns and
of the height of the terminal hypertrophic chondrocytes
(Kember, 1993). In fact, there is an apparent positive linear
relationship between the rate of longitudinal bone growth
and the volume of hypertrophic chondrocytes (Breur et al.,
1991). We think that hypoproliferation in the zone of
actively dividing chondrocytes results in a reduction in the
rate of production and maturation of hypertrophic zone
chondrocytes in our mutants, leading in turn to a signifi-
cant reduction in the height of the primary spongiosa (Fig.
5a). As a consequence, the mutants have shorter bones. The
same relationships, including reduced heights of the pri-
mary spongiosa, were also observed in distal femora exam-
ined at p60 (data not shown).
Parallel ossification delays were observed in epiphyseal
chondrocytes, but predominantly in I and D mutants. In
ontrast, the secondary ossification center of the G mutants
id not differ dramatically from wild-type at the examined
ges (p22 and p30), possibly because the ossification process
ad progressed significantly by the time the effects of the
hr mutation were first manifested (p15). At p30, most of
he epiphyseal chondrocytes in W and G mice were already
ypertrophic, whereas abundant proliferating chondrocytes
ere still detectable in the epiphyses of I and D mutants
Fig. 4g). This difference in the pace of the differentiation
rogram was further evident at p130 (Fig. 4h). Thus, the W
nd G mice had practically reached a steady state, and their
rowth plates were approaching closure, while the epiphy-
es were completely converted into bone. In contrast,
ypertrophic chondrocytes were still discernible in the
piphyses of I and D mutants. Analogous observations were
ade in the patella (a bone also developing by endochondral
ssification), which at p130 illustrates very characteristi-
ally the relative ossification delays in the mutants (Fig. 4i).
Proliferation assays. To examine whether our interpre-
ation (postulating hypoproliferation as the cause of our
orphological observations) could be supported by direct
vidence, we assessed the effects of the Ghr and Igf1
utations on chondrocyte proliferation by BrdU labeling
or 1 h prior to sacrifice. Considering that the duration of
he S phase in mouse chondrocytes is ;7 h (;36 h average
ell cycle time; Vanky et al., 1998), the brief pulse of BrdU
ould identify exclusively S-phase proliferating cells, thus
s of reproduction in any form reserved.
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proliferative zone chondrocytes that incorporated BrdU in
wild-type mice was 18.7%. Considering this value as nor-
mal (100% of attainable incorporation), we observed a
significant reduction in all of the mutants (the correspond-
ing value was ;63%N in G or I mutants and ;43%N in D
mutants; Table 3). In agreement with previous evidence
(Vanky et al., 1998), incorporation was observed only in the
upper 60% of the proliferative zone (Fig. 5b). This snapshot
of BrdU labeling indices is consistent with our interpreta-
tion of reduced chondrocyte proliferation as a consequence
of the mutations under study. Diminished incorporation
was also observed in the stromal cells of the mutants (Fig.
5c). Although detailed counting of these cells representing
the presumptive precursors of osteoblasts was not per-
formed, we noticed that their numbers were reduced in the
mutants. We note that, in a previous study (Wang et al.,
1999), a difference in BrdU labeling indices in proliferative
zone chondrocytes was not observed between wild-type and
Igf1 null mice, for unknown reasons.
In situ hybridization analyses. From our comparative
histological analysis we concluded that, except for the size
of hypertrophic chondrocytes, differentiation defects or
histopathological changes were absent from our mutants.
To support this conclusion further, we performed in situ
hybridization analysis to examine the expression of colla-
gen markers. In particular, we tested for expression of type
II collagen mRNA occurring predominantly in proliferating
chondrocytes, for expression of type X collagen mRNA that
is restricted to hypertrophic chondrocytes, and for expres-
sion of type I collagen mRNA that is restricted to osteo-
blastic cells (see Lee et al., 1994). Comparative analysis of
the results (Figs. 6a–6c) did not reveal any differences in
signal localization between mutants and controls, although
subtle, and difficult to assess, differences in signal intensity
may exist.
Importantly, we also used in situ hybridization analysis
to examine the expression of Ghr and Igf1 in the growth
plate. Such information was crucial for interpretation of the
GH and IGF1 relationship in bone development, especially
considering that previously reported data are either incom-
plete or conflicting.
To our knowledge, Ghr expression in the proximal tibial
epiphysis has not been examined by in situ hybridization,
but data from immunohistochemical analyses of rat speci-
mens are available. In two of three studies (Symons et al.,
1996; Vidal et al., 1997), all using the same monoclonal
antibody, stained cells were localized in the articular and
epiphyseal cartilage, the secondary ossification center, the
resting zone of chondrocytes, and also in the primary
spongiosa and bone marrow cells. However, the prolifera-
tive and hypertrophic chondrocytes were reportedly nega-
tive for immunostaining. In contrast, in a third study
(Edmondson et al., 2000), a positive signal was detected
immunohistochemically in proliferative chondrocytes, in
agreement with similar results for rabbit and human
growth plates (Barnard et al., 1988; Werther et al., 1990).
Copyright © 2001 by Academic Press. All rightIn rodents, immunoreactivity for IGF1, and also for type
IGF receptor (IGF1R), was detected in cells of the articular
nd epiphyseal cartilage, secondary ossification centers,
roliferating (but not hypertrophic) chondrocytes, and bone
arrow cells (Joseph et al., 1999; Maor and Karnieli, 1999;
Kikkawa et al., 2000). On the other hand, Igf1 expression
examined in rats and mice by in situ hybridization at
various postnatal ages up to 7 weeks (Shinar et al., 1993;
Wang et al., 1995) indicated the presence of transcripts in
perichondrium, periosteum, and presumptive osteoblasts of
epiphyseal and metaphyseal trabecular bone, but not in
growth plate chondrocytes, which nevertheless appeared to
express Igf1r (Wang et al., 1995). These results, however,
were not in agreement with other in situ hybridization
reports (Nilsson et al., 1990; Lazowski et al., 1994; Hanna et
al., 1995) showing Igf1 expression in rat growth plate
chondrocytes. It is likely that, because of low levels of Igf1
transcription in chondrocytes, detection of signal by in situ
hybridization, which is feasible under conditions of induced
expression (see, for example, Rihani-Bisharat et al., 1998),
may depend on assay sensitivity.
The uncertainty about the expression of Ghr and Igf1
genes in the same cells, and more specifically in proliferat-
ing chondrocytes, generated vexing questions in regard to
the interpretation of our morphological and BrdU incorpo-
ration results. Therefore, we attempted to evaluate the
situation directly by performing nonradioactive in situ
hybridization experiments of high sensitivity (see Materials
and Methods). In tibia sections from wild-type mice, we
observed reproducibly a relatively weak, but specific, hy-
bridization signal for Ghr transcripts in proliferating chon-
drocytes using an antisense probe, whereas the results with
a sense (control) probe were negative (Fig. 6d). Similarly,
positive hybridization signal for Igf1 was detected in the
same cells (and in addition in hypertrophic chondrocytes)
with an antisense, but not with a sense, probe (Fig. 6e). In
fact, the results with a sense probe were indistinguishable
from those obtained with an antisense probe using sections
from Igf1 null mutants. Importantly, when these experi-
ments were repeated with mutants lacking GHR, the re-
sults showed unequivocally that Igf1 gene expression was
retained in the absence of GH action (Fig. 6e). It was not
possible, however, to ascertain whether the level of expres-
sion was normal or reduced.
The dual effector theory is not tenable. Our analysis of
linear growth, although not extensive, revealed that GH
and IGF1 have independent and overlapping functions in
chondrocytes, since the phenotype of double mutants is
more severe than that manifested in either class of single
mutant. However, in contrast with the important interde-
pendence between the GH and the IGF1 signaling roles in
terms of whole body weight, the independent actions of
these growth effectors appear to predominate in chondro-
cytes, whereas their overlapping function has secondary
significance. Thus, when the values for body or tibia length
at steady state (p130; Table 3) are taken into consideration,
the sum of the deficits of the G and I single mutants from
s of reproduction in any form reserved.
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158 Lupu et al.wild type is only slightly larger than the corresponding
deficit of the double mutant, revealing that the contribu-
tion of overlapping function to bone growth does not exceed
;5% of the total (details of the calculations are not shown).
Whether this functional overlap of small magnitude con-
sists of two components, GH-induced IGF1 function in
chondrocytes and endocrine function of IGF1, cannot be
ascertained from our results.
Consistent with our conclusion that in chondrocytes the
independent GH and IGF1 actions predominate, we found
that the degree of hypoproliferation, as assessed by histo-
logical and BrdU incorporation data, did not differ in mag-
nitude between mutants lacking IGF1 or GHR, and yet the
same cell population (proliferating chondrocytes) was af-
fected. These observations do not support the dual effector
theory, which was initially proposed for adipocytes (Green
et al., 1985) and later adapted for chondrocytes (Green et al.,
985; Isaksson et al., 1987). This theory posits that GH
ction is essential for promotion of the differentiation of
rogenitor cells (resting zone prechondrocytes), whereas
GF1 acts on proliferating chondrocytes as a mitogen and
timulates subsequent clonal expansion. Thus, a postulate
hat was repeatedly emphasized (see Ohlsson et al., 1998,
nd other references therein) is that GH and IGF1 act on
ifferent growth plate cell populations (or compartments).
his view is clearly inconsistent with our results demon-
trating that both Igf1 and Ghr are expressed in the same
one of proliferative chondrocytes, that they are function-
lly equally potent and almost completely independent,
hat they are both involved in proliferation, and that differ-
ntiation resulting in the appearance of chondrocyte col-
mns does occur in the absence of either or both of these
ffectors.
CONCLUDING REMARKS
Taking into consideration the genetic evidence that we
have provided, the components of the GH/IGF1 relation-
ship can be viewed as follows. GH is involved in the
production of hepatic IGF1, which reaches the circulation
and behaves as a bona fide hormone (the classic “somato-
edin”). It is notable, in this regard, that injections of this
actor are known to augment growth reproducibly (see, for
xample, van Buul-Offers et al., 1986, 1988, 2000; Chatelain
et al., 1991; Hunziker et al., 1994). This endocrine function
(component 1) corresponds to the overlapping activity of
GH and IGF1, together with some relatively minor overlap
of GH-dependent IGF1 production in a few extrahepatic
tissues (component 2). In the majority of extrahepatic
tissues, however, GH and IGF1 act independently (compo-
nents 3 and 4). Whole body growth is mostly manifested as
the sum of variable effects of these components in various
tissues.
When GH is lacking, as is the case in Snell and lit
mutants, administration of GH has greater effect than
administration of IGF1 because, in the GH/IGF1 relation-
Copyright © 2001 by Academic Press. All rightship, GH is upstream and also has independent action.
Although the circulating IGF1 is diminished in the absence
of GH, the local (GH-independent IGF1) is still active.
Thus, administration of IGF1 simply restores the missing
endocrine function. This function is also restored by GH
administration and, in addition, the missing IGF1-
independent GH actions are also restored (greater sum of
activity). Similarly, because of the described relationships,
wild-type animals respond more to GH than to IGF1 ad-
ministration (normal functions are augmented; Won and
Powell-Braxton, 1998). In contrast to normal mice or mu-
tants lacking GH, the growth of mutants lacking IGF1
improves only by IGF1 administration (Won and Powell-
Braxton, 1998). These mice appear to remain unresponsive
to GH (Won and Powell-Braxton, 1998; Liu and LeRoith,
1999) because GH alone makes a relatively small contribu-
tion to growth, as we have shown here, which is potentially
counterbalanced by inhibition of GHR dimerization due to
ligand excess (see Daughaday, 1997). In fact, excess is
extreme in this case, since exogenous GH is added to the
already increased concentration of circulating hormone due
to the absence of the negative feedback loop.
It is notable that, although under normal circumstances,
there is very significant GH/IGF1 functional overlap in
terms of whole body growth, in artificial cases of overex-
pression, compensatory effects of large magnitude are pos-
sible exactly because of the independence of the GH and
IGF1 components, as revealed by the following classic
experiment. IGF1 overexpression in transgenic mice re-
sulted in a 30% increase of body weight over normal that
was accompanied by a 50% increase in serum IGF1
(Mathews et al., 1988). When these transgenics were
crossed with dwarf transgenic mice lacking GH (pituitary
somatotrophs were ablated by diphtheria toxin expression;
Behringer et al., 1988), the progeny were indistinguishable
from wild type, despite the absence of GH (Behringer et al.,
1990). Also, quite remarkably, high GH expression in the
liver from an adenovirus construct was able to reverse
completely the phenotype in lit mice by catch-up growth
(Hahn et al., 1996).
Our results, placed in the framework of the growth
control field, indicate that the IGF system is the major
determinant of both embryonic and postnatal growth that is
modulated in the postnatal period by GH. Thus, the GH and
IGF1 effectors, acting in concert, participate in the conver-
gence of most growth signaling pathways. Although details
about their exact relationship are still missing, we think
that the simple view of a four-component system presented
above is not only compatible with most of the available
evidence, but can also serve as a springboard for further
experimental testing.
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